<?xml version="1.0" encoding="UTF-8"?>
<p>The HAPI H5N1 virus has continuously crossed the species barrier and frequently infected humans since the confirmed human case reported to WHO in 2003 (
 <ext-link ext-link-type="uri" xlink:href="http://www.who.int/influenza/human_animal_interface/EN_GIP_20120810CumulativeNumberH5N1cases.pdf" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.who.int/influenza/human_animal_interface/EN_GIP_20120810CumulativeNumberH5N1cases.pdf</ext-link>). Although the ability to generate highly transmissible forms of H5N1 in the laboratory enables investigators to further elucidate the mechanism of virus transmission, such advancement poses a considerable threat to public health, raising concerns over issues of biosafety and dual-use research 
 <xref rid="pone.0053568-Faden1" ref-type="bibr">[22]</xref>â€“
 <xref rid="pone.0053568-LeDuc1" ref-type="bibr">[26]</xref>. Thus, the search for readily available effective vaccines is more than justified to prevent seasonal epidemics and prepare for unpredicted H5N1 virus infections 
 <xref rid="pone.0053568-Fouchier1" ref-type="bibr">[27]</xref>.
</p>
